Therachon
Basel
About Therachon
Therachon is a global biotechnology company focused on developing medicines for rare, genetic diseases that currently have no available treatments. The company’s lead pipeline candidate, TA-46, is a novel protein therapy in development for achondroplasia, the most common form of short-limbed dwarfism. Therachon is headquartered in Basel, Switzerland, with research labs in Nice, France.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $10K – $50K
- Total funding: $100.0M
- Funding stage: M&A
- Last round: Series B (Aug 2018)
- Website: therachon.com
- Phone: +41798989209
Industries & Categories
Biotechnology, Medical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/therachon-87851 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.